KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Gross Margin: 2009-2025

Historic Gross Margin for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to 81.95%.

  • Biomarin Pharmaceutical's Gross Margin rose 722.00% to 81.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 81.32%, marking a year-over-year increase of 247.00%. This contributed to the annual value of 79.67% for FY2024, which is 166.00% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Gross Margin is 81.95%, which was up 0.16% from 81.82% recorded in Q2 2025.
  • Biomarin Pharmaceutical's Gross Margin's 5-year high stood at 81.95% during Q3 2025, with a 5-year trough of 72.72% in Q4 2022.
  • Its 3-year average for Gross Margin is 79.48%, with a median of 79.66% in 2025.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Gross Margin surged by 1,427bps in 2021 and then tumbled by 325bps in 2024.
  • Biomarin Pharmaceutical's Gross Margin (Quarterly) stood at 73.38% in 2021, then plummeted by 66bps to 72.72% in 2022, then surged by 594bps to 78.66% in 2023, then surged by 313bps to 81.78% in 2024, then soared by 722bps to 81.95% in 2025.
  • Its Gross Margin stands at 81.95% for Q3 2025, versus 81.82% for Q2 2025 and 79.66% for Q1 2025.